Compare Abeona Therapeutics Inc (ABEO) vs Five Below Inc (FIVE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Five Below Inc — how do they compare? Abeona Therapeutics Inc trades at $6.69 (market cap $373.32M), while Five Below Inc trades at $178.13 (market cap $9.75B). The key difference: Five Below Inc is far larger — about 26.1× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Five Below Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | FIVE | |
|---|---|---|
Market Cap | $373.32M | $9.75B |
Sector | Health | Consumer Staples |
52-Week High | $7.23 | $247.71 |
52-Week Low | $4.17 | $128.78 |
Enterprise Value | $228.22M | $10.63B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Five Below (FIVE) trades at $176.25, down 3.39% with a bearish technical signal despite strong earnings beats. The company shows solid revenue growth from $3.88B in 2025 to projected $5.1B in 2026, with net income margin improving to 8.67%. Recent news highlights digital marketing success and leadership appointments driving customer engagement. Technical indicators show oversold conditions with RSI at 24.82, while support levels begin at $174.
Analyst consensus remains strongly bullish with 58% buy ratings and $253 price target, representing 44% upside. Key risks include execution of expansion plans and consumer spending sensitivity. The combination of strong fundamentals, positive analyst sentiment, and current technical oversold conditions presents a compelling opportunity for growth investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Five Below Inc
Five Below is a value-oriented retailer that operated 1,190 stores in the United States as of the end of fiscal 2021. Catering to teen and preteen consumers, stores feature a wide variety of merchandise, the vast majority of which is priced below $6. The assortment focuses on discretionary items in several categories, particularly leisure (such as sporting goods, toys, and electronics
Read more on FIVE →
